In the News
In the CRISPR pipeline – Rachel Haurwitz, CEO Caribou Biosciences
In June I met Rachel Haurwitz, CEO of Caribou Biosciences, at the Pioneers Festival in Vienna and we talked about the future of gene-editing and the CRISPR pipeline.
Caribou Biosciences is a biotechnology startup that develops cellular engineering and analysis solutions based on CRISPR-Cas technology. It was founded by members of the Doudna Laboratory at the University of California. Rachel is Caribou´s CEO. The Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business.
MIT Technology Review: 35 Innovators Under 35
Meet the people who are taking innovations like CRISPR and flexible electronics and turning them into businesses.
Caribou Bioscience’s CEO on CRISPR’s legal and ethical challenges
Caribou Bioscience co-founder and CEO Rachel Haurwitz joined us onstage at Disrupt this morning to help unpack some of the myriad complexities around her company’s pioneering work in the field of CRISPR biology. The gene editing tool has been the source of tremendous excitement over the last several years for its potential to help science hack everything from disease to food supply.
Nature Biotechnology First Rounders Podcast
Rachel Haurwitz is co-founder, president and CEO of Caribou Biosciences. In her discussion with Nature Biotechnology, she explains what drew her into the sciences, how her father's journalism career brought their family to Austin, Texas, and how she found herself at the cutting edge of CRISPR technology.
Researchers Publish Two New Methods for Analysis of CRISPR Off-Target Effects
Two studies published simultaneously in Nature Methods yesterday describe new methods for analyzing the off-target effects of CRISPR/Cas-9 genome editing. One method identifies off-target mutations associated with cell-type-specific SNPs, while the other detects potential off-target cleavage sites.